Pediatrix Medical Group, Inc. (MD) · Oct 29, 2026 · Earnings
Beat — Adjusted EPS $0.72 vs ~$0.65 consensus
Pediatrix earnings beat Q3 expectations and lifted the low end of 2026 EBITDA guidance, though same-unit growth and margins remain soft.
Pediatrix is still executing a shift toward hospital-based and maternal-fetal medicine services, while using acquisitions and revenue-cycle changes to rebuild growth and efficiency. That backdrop was already known; this quarter mainly tests whether those moves are producing cleaner operating leverage.
The quarter beat the published bar, but not by a wide margin. Adjusted EPS was $0.72 versus a published consensus of about $0.65, while revenue was $501.4 million versus roughly $498.2 million expected. The filing also says volume and pricing were ahead of management’s expectations:
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Net revenue (Financial Highlights) | $501.4M (+1.7%) | $492.9M | ~$498.2M |
| Adjusted EPS (Adjusted EPS reconciliation) | $0.72 (+7.5%) | $0.67 | ~$0.65 |
| Adjusted EBITDA (Adjusted EBITDA reconciliation) | $85.5M (-2.1%) | $87.3M | |
| Same-unit revenue (Operating Results) | +0.6% |
The quality of the beat is mixed because operating leverage deteriorated. Revenue rose 1.7%, but adjusted EBITDA fell 2.1% as salaries and other costs grew faster than the existing business; the company explicitly attributed the decline to higher expenses relative to revenue growth at existing units. Same-unit revenue increased only 0.6%, with patient volume contributing 0.3%, while hospital-based services and NICU days both declined year over year.
The most important incremental signal is a higher EBITDA floor. Pediatrix moved full-year 2026 Adjusted EBITDA guidance to $290 million-$300 million from the previously reaffirmed $280 million-$300 million range, raising the low end while leaving the ceiling unchanged. That suggests confidence in the earnings floor, but not a broad acceleration in the business.
Buybacks helped per-share results, while cash generation was softer. Weighted average diluted shares fell to 79.7 million from 85.6 million, supporting the adjusted EPS increase, but operating cash flow declined to $117.7 million from $138.1 million and cash balances fell to $311.9 million from $375.2 million at year-end. The company spent $83.0 million on repurchases during the quarter, so the EPS beat reflects both operating performance and a smaller share count.
Bottom line: This is a modestly better-than-expected quarter with a meaningful raise to the EBITDA floor, but the underlying operating story is not clean: same-unit growth is thin and costs are still outrunning revenue. The event advances the turnaround, though it does not yet prove durable margin expansion.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!